Data protection Impressum

Biotech

Oryl Photonics has joined the Fast and Accurate Solubility for Sustainability (FASS) project, receiving a EUR 2.5 million EIC Transition grant to develop a novel laboratory instrument for drug solubility measurement.

EPFL spin-off Oryl Photonics joins a EUR 2.5 million European project

7 August 2024

Biopôle is joining forces with Swiss Healthcare Startups to extend the Vanguard accelerator to digital health start-ups in German-speaking Switzerland, while also welcoming Hôpital de La Tour to its Corporate Partnership Programme.

Biopôle expands its accelerator program and welcomes new corporate partner

5 August 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (July 2024)

17 July 2024

Asceneuron has secured USD 100 million in Series C funding to advance its mission of developing OGA inhibitors for neurodegenerative diseases like Alzheimer's.

Asceneuron raises USD 100 million to advance Alzheimer’s treatment

16 July 2024

Global demand for biologics is at an all-time high, and Western Switzerland is positioning itself as a key player in meeting that demand.

Biomanufacturing in Western Switzerland

The FONGIT Innovation Fund has awarded funding to three cutting-edge tech projects: CHF 100,000 seed loans for returning winners Planeto and HekeTiss, and a CHF 50,000 grant for newcomer LightEye.

CERN and UNIGE spin-offs awarded FIF Funding

2 July 2024

BioAlps, the life sciences cluster of Western Switzerland, offers a dynamic network, an innovative and supportive environment and direct access to the region's vibrant life sciences ecosystem.

BioAlps, Western Switzerland’s life sciences cluster

Top Stories Western Switzerland

Top Stories from Western Switzerland (May 2024)

28 May 2024

Vaud-based life sciences company Limula has secured CHF 6.2 million to democratize access to life-saving cell and gene therapies.

Limula secures CHF 6.2 million to advance automated cell therapy platform

21 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

1 2 3 4 5 6 7 8 9 10 … 20